MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

Table 2 Overview of miRNAs with significantly different levels of expression in rectal tumors of responders and non-responders to neoadjuvant chemoradiotherapy

MiRNAs	R	NR	Fold change (NR vs R)	P-value	Putative targets^†#
miR-450b-5p	U	D	0.07	0.0003	RANBP9, SLC19A2, XIAP, RGMB, SMAD2, SERPINA5, SOX2, TCF5, TIMP2, TGFBR2
let-7e	U	D	0.48	0.0075	NRAS^#, KRAS^#, SOCS1^#, HMGA2^#, ABCC5, HOXD1, MASP1, ERCC6, IGF1
miR-450a	U	D	0.16	0,0104	MAP3K2, RAB31, TOPBP1, CREB1, DNMT3A, EGFR, ERCC5
miR-99a*	U	D	0,21	0,0163	RAD51C, RAD9B, TIAM1, TMEM87a, TMEM71, SOCS4, RANBP4, RANBP6
miR-190b	D	U	4.03	0.0290	CDKN1B, MUC17, MYCBP2, SMAD2, TCF4, CASP2, TP53INP1
miR-29b-2*	D	U	4.25	0.0375	AKT3, RANBP9, PARP2, HDAC5, CDKN3, AGR2, SLC19A2, FOXN3
miR-215	D	U	4.40	0.040	ZEB2^#, ALCAM^#, TYMS (TS) ^#, DHFR^#, EREG, HOXB9, NOD2
miR-196b	U	D	0.42	0,043	HOXB8^#, HOXC8^#, ERG^#, BACH1^#, FAS, TBRG1, TOX3

Legend: R – responders, NR – non-responders, D – down-regulated expression, U – up-regulated expression. ^# Target is experimentally validated. ^† Putative targets were predicted using miRWalk database and miRanda algorith (21) and subsequently selected on the basis of their significance in tumor biology, particularly in the processes of cell survival and resistance to anti-cancer treatment.

ISSN: 1748-717X